Title : Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial.

Pub. Date : 2009 Nov

PMID : 19681813






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Tacrolimus, a cornerstone immunosuppressant, is widely available as a twice-daily formulation (Tacrolimus BID). Tacrolimus BH3 interacting domain death agonist Homo sapiens
2 Tacrolimus, a cornerstone immunosuppressant, is widely available as a twice-daily formulation (Tacrolimus BID). Tacrolimus BH3 interacting domain death agonist Homo sapiens
3 This study compared the pharmacokinetics (PK) of tacrolimus in de novo kidney transplant patients treated with Tacrolimus QD or Tacrolimus BID. Tacrolimus BH3 interacting domain death agonist Homo sapiens
4 Mean AUC(0-24) of tacrolimus on day 1 was approximately 30% lower for Tacrolimus QD than Tacrolimus BID (232 and 361 ng.h/mL, respectively), but was comparable by day 4. Tacrolimus BH3 interacting domain death agonist Homo sapiens
5 Tacrolimus QD can be administered once daily in the morning on the basis of the same systemic exposure and therapeutic drug monitoring concept as Tacrolimus BID. Tacrolimus BH3 interacting domain death agonist Homo sapiens